Last updated: 2026-09-06 01:10:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Mineralys Therapeutics, Inc. (MLYS) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $28,20, with a market capitalization of $2,50B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $22,30 to $47,65. This page covers its latest market performance, valuation, price trends and company information.
$2,50B | |
$28,00 | |
$47,65 | |
$5,85 | |
$28,27 | |
520,75K | |
-- | |
-- | |
$47,65 | |
$22,30 | |
-- | |
-- |
Mineralys Therapeutics, Inc. (MLYS) last closed at $28,27 as of 2026-09-04 23:48:00, unchanged from the previous close of $28,27.
During the latest regular trading session, MLYS traded between $5,85 and $47,65, with a volume of 520,75K shares. The closing price was near the middle and near the lower end of its 52-week range.
Over the past seven days, Mineralys Therapeutics, Inc. (MLYS) moved from $25,42 to $28,20, representing a gain of 10,94% ($2,78).
The stock traded between $27,39 and $28,58 during the period. The latest price is near the upper end of the 7-day range, indicating strong upward.
The average daily volume was 1,01 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 23,3%
MLYS is currently trading at $28,20, placing it 23,3% of the way from its 52-week low of $22,30 to its 52-week high of $47,65. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 76 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Mineralys Therapeutics, Inc. (MLYS) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.